Ji-young Park
Korea University · 医学
研究室紹介
Professor Ji-young Park's research lab focuses on the intersection of metabolism, tumor microenvironment, and chronic disease pathogenesis. The lab investigates how adipocyte-derived factors, such as endotrophin and glucose-6-phosphate dehydrogenase (G6PD), contribute to tumor progression, insulin resistance, and metabolic dysfunction in obesity. Key research directions include the role of stromal cells in cancer biology, the impact of metabolic reprogramming in adipocytes on systemic inflammation, and the identification of novel therapeutic targets in obesity-related diseases. The lab integrates molecular biology, metabolic profiling, and translational models to uncover mechanisms linking metabolism and disease.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Two viral proteases of severe acute respiratory syndrome coronavirus (SARS-CoV), a chymotrypsin-like protease (3CL(pro)) and a papain-like protease (PL(pro)) are attractive targets for the development of anti-SARS drugs. In this study, nine alkylated chalcones (1-9) and four coumarins (10-13) were isolated from Angelica keiskei, and the inhibitory activities of these constituents against SARS-CoV proteases (3CL(pro) and PL(pro)) were determined (cell-free/based). Of the isolated alkylated chalco
Simvastatin, a cholesterol-lowering agent, is mainly metabolized by CYP3A4/5. The objective of this study was to investigate the effect of CYP3A5*3 genotype on the pharmacokinetics of simvastatin in humans. Twenty-two men with CYP3A5*1/*1 (n = 4), CYP3A5*1/*3 (n = 8), or CYP3A5*3/*3 (n = 10) genotypes were enrolled. Each subject ingested a 20-mg dose of simvastatin, and plasma simvastatin concentrations were measured for 12 hours after dosing. The mean (+/-SD) area under the plasma concentration
BACKGROUND AND OBJECTIVE: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone. Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans. METHOD: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for
As homeland security policy makers seek to funnel scarce resources to the most vulnerable areas, geographic impact studies have become ever more crucial since the events of September 11, 2001. In the sense that the Los Angeles and Long Beach ports are among the largest in the world, service interruptions there would have nation-wide economic impacts. Because foreign and domestic imports are in greater volumes than exports, the interruption of imports should be examined with a supply-side MRIO-ty
The effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide suggests that rifampin affects the disposition of gliclazide in humans, possibly by the induction of cytochrome P450 2C9. Concomitant use of rifampin with gliclazide can considerably reduce the glucose-lowering effects of gliclazide.
BACKGROUND AND OBJECTIVE: Carbamazepine (CBZ) is metabolized mainly by the CYP3A family of enzymes, which includes CYP3A4 and CYP3A5. Several studies have suggested that the CYP3A5*3 genotype influences the pharmacokinetics of CYP3A substrates. The present study aimed to assess the effect of the CYP3A5*3 genotype on serum concentration of CBZ at the steady-state in Korean epileptic patients. METHOD: The serum concentrations of CBZ in 35 Korean epileptic patients were measured and their CYP3A5 ge
CYP3A5*3/*3 carriers exhibited lower plasma amlodipine concentrations than CYP3A5*1 carriers. These findings suggest that the polymorphic CYP3A5 gene affects the disposition of amlodipine and provides a plausible explanation for interindividual variability in amlodipine disposition.
Our results provide in vivo evidence of the involvement of CYP3A in the disposition of risperidone and 9-hydroxyrisperidone. In addition to CYP2D6, treatment with CYP3A inhibitor(s) including itraconazole may influence clinical symptoms and risperidone side effects.
The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam.